Daily aspirin may benefit some high-risk people without cardiovascular disease (CVD), according to an individualized benefit-harm analysis in the Annals of Internal Medicine.
Roughly 250,000 adults aged 30 to 79 without established CVD had their cardiovascular risk assessed with software integrated into the electronic health record. Researchers estimated the net effect of aspirin for each patient.
If one CVD event is assumed to be as severe as one major bleed, then aspirin would provide a net benefit to 2.5% of women and 12.1% of men over 5 years’ follow-up. If the assumption changed to one CVD event being equivalent to two major bleeds, then 21% of women and 41% of men would see a net benefit from aspirin.
The study results are limited by the fact that the Effects of aspirin on cancer outcomes were not considered. Also, applicability to non–New Zealand populations was not assessed.
Read the full article here.
Source: NEJM Journal Watch & Annals of Internal Medicine